Emmanuel Caeymaex

Emmanuel leads the worldwide development and commercialization of innovative patientoriented solutions that create value for people suffering from autoimmune disorders, such as psoriatic arthritis, psoriasis, axial spondyloarthritis, lupus, rheumatoid arthritis, Crohn’s disease as well as osteoporosis. He is also in charge of UCB's corporate activities in the US.